RXRX Quote, Financials, Valuation and Earnings

Apellis Pharmaceuticals has a net margin of -3965.99% compared to Recursion Pharmaceuticals's net margin of -17.11%. Recursion Pharmaceuticals's return on equity of -77.06% beat Apellis Pharmaceuticals's return on equity of -83.06%.

Recursion Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 126.7%. On the other hand Apellis Pharmaceuticals has an analysts' consensus of $43.15 which suggests that it could grow by 130.75%. Given that Apellis Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Apellis Pharmaceuticals has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.967%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Apellis Pharmaceuticals pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $4.5M, which are smaller than Apellis Pharmaceuticals quarterly revenues of $212.5M. Recursion Pharmaceuticals's net income of -$178.9M is lower than Apellis Pharmaceuticals's net income of -$36.4M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Apellis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 18.62x versus 2.97x for Apellis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of -3965.99% compared to Recursion Pharmaceuticals's net margin of 16.9%. Recursion Pharmaceuticals's return on equity of -77.06% beat Corcept Therapeutics's return on equity of 23.78%.

Recursion Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 126.7%. On the other hand Corcept Therapeutics has an analysts' consensus of $143.25 which suggests that it could grow by 103.22%. Given that Recursion Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Recursion Pharmaceuticals is more attractive than Corcept Therapeutics.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $4.5M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Recursion Pharmaceuticals's net income of -$178.9M is lower than Corcept Therapeutics's net income of $30.7M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 56.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 18.62x versus 11.85x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of -3965.99% compared to Recursion Pharmaceuticals's net margin of 39.44%. Recursion Pharmaceuticals's return on equity of -77.06% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Recursion Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 126.7%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 58.29%. Given that Recursion Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Recursion Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $4.5M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Recursion Pharmaceuticals's net income of -$178.9M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 16.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 18.62x versus 5.44x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Enanta Pharmaceuticals has a net margin of -3965.99% compared to Recursion Pharmaceuticals's net margin of -131.44%. Recursion Pharmaceuticals's return on equity of -77.06% beat Enanta Pharmaceuticals's return on equity of -70.18%.

Recursion Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 126.7%. On the other hand Enanta Pharmaceuticals has an analysts' consensus of $15.14 which suggests that it could grow by 239.53%. Given that Enanta Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Enanta Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Recursion Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Enanta Pharmaceuticals has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.793%.

Recursion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enanta Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals pays -- of its earnings as a dividend. Enanta Pharmaceuticals pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals quarterly revenues are $4.5M, which are smaller than Enanta Pharmaceuticals quarterly revenues of $17M. Recursion Pharmaceuticals's net income of -$178.9M is lower than Enanta Pharmaceuticals's net income of -$22.3M. Notably, Recursion Pharmaceuticals's price-to-earnings ratio is -- while Enanta Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals is 18.62x versus 1.42x for Enanta Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.